RxDoctor Payments Data

Joseph Pace, MD

Internal Medicine · Bradenton, FLNPI 1205823838

Payments from drug & device makers

$149,183in general payments, 2019–2025

Across 801 payments — averaging $186.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$108K
  • Johnson & Johnson$13K
  • Boston Scientific$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
  • Abbott$4K
  • Medtronic$3K
  • plus $9K from 51 others

What the payments were for

  • Consulting fees$20,60030%
  • Speaking & faculty fees$16,40024%
  • Travel & lodging$6,4239%
  • Food & beverage$25,32537%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,183 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$356,386
Medicare patients
2,179
Services billed
5,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban152$173,665
EliquisApixaban107$139,845
Repatha SureclickEvolocumab69$70,307
EntrestoSacubitril/Valsartan59$68,478
JardianceEmpagliflozin30$35,672
FarxigaDapagliflozin Propanediol16$21,456
Nebivolol Hcl67$4,457
ClopidogrelClopidogrel Bisulfate225$2,945
Propafenone Hcl35$2,102
Ranolazine ErRanolazine19$1,817
Atorvastatin Calcium178$1,752
Bumetanide30$1,469
Bisoprolol Fumarate61$1,411
Amiodarone Hcl61$1,232
Metoprolol Succinate85$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13,181$173,665152 claims
PfizerEliquis$372$139,845107 claims
NovartisEntresto$275$68,47859 claims
Boehringer IngelheimJardiance$291$35,67230 claims
AstraZenecaFarxiga$928$21,45616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →